Tesla Stock Plummets 1.93% on $35.27 Billion Record Volume as Production Hurdles and Regulatory Shifts Spark Market Volatility

Generated by AI AgentAinvest Volume Radar
Tuesday, Sep 23, 2025 7:59 pm ET1min read
TSLA--
Aime RobotAime Summary

- Tesla shares fell 1.93% on Sept 23, 2025, with record $35.27B trading volume driven by production delays at Berlin Gigafactory and regulatory uncertainties.

- Production challenges linked to local permitting issues raised concerns about Q4 targets, while expanded CATL battery partnership provided partial supply chain stability.

- California's revised EPA credit policy reducing EV incentives sparked debates over long-term profitability, compounding valuation risks for growth-focused investors.

On September 23, 2025, , securing the top position in market activity. The stock’s performance was influenced by mixed signals from production updates and regulatory developments.

Reports highlighted Tesla’s ongoing challenges at its Berlin Gigafactory, . Meanwhile, , offering some stability amid supply chain uncertainties. .

Regulatory scrutiny also impacted sentiment. A revised EPA credit policy in California, which reduces incentives for zero-emission vehicles, sparked debates about long-term profitability. While Tesla’s leadership in EV innovation remains intact, .

To run this back-test accurately I need to pin down a few practical details: 1. Universe • All U.S. listed common stocks, or a narrower list (e.g., current S&P 500 constituents)? 2. . , , . • Is this acceptable, or would you prefer a different convention (e.g., buy at the same-day close)? 3. ? ? 4. , ? If the above default choices (U.S. common stocks, equal-weight, enter next-day open, , zero explicit costs) work for you, just let me know and I’ll proceed with the data pulls and back-test. Otherwise, specify the adjustments you’d like.

Hunt down the stocks with explosive trading volume.

Latest Articles

Stay ahead of the market.

Get curated U.S. market news, insights and key dates delivered to your inbox.

Comments



Add a public comment...
No comments

No comments yet